Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data.

Patients in the Cb group tended to be younger versus non-Cb counterparts; however, this difference did not reach statistical significance (49-year-old versus 52-year-old, respectively; p = 0.34).

also in 111,027 other papers

Still, patients who received anthracycline plus taxane regimens displayed a clear trend towards increased pCR compared to first or second generation regimens, with or without Cb [ 14 ].

also in 19,460 other papers